Literature DB >> 3922373

Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid.

H Patscheke.   

Abstract

The effect of the thromboxane (TX) synthase inhibitors dazoxiben and imidazole on platelet activation by endogenous and exogenous arachidonic acid (AA) was tested with human washed platelets. Dazoxiben (1-20 microM) inhibited the formation of TXB2 and markedly enhanced the shape change, aggregation, and (3H)serotonin release induced by added AA or when prostaglandin synthesis from endogenous AA was triggered by collagen, hydrogen peroxide or methyl mercury chloride (methyl-Hg). Platelet activation by hydrogen peroxide (20-1200 microM) or methyl-Hg (1-5 microM) was entirely dependent on endogenous prostaglandin (PG) synthesis since acetylsalicylic acid (ASA), indomethacin or the cyclic endoperoxide/TXA2-antagonist BM 13.177 counteracted these stimulants with and without dazoxiben. Apparently, the potentiation is due to accumulating cyclic endoperoxides which during TX synthase inhibition reach greater platelet-activating potency than TXA2. Albumin or human platelet-poor plasma inhibited the platelet activation by hydrogen peroxide and methyl-Hg and suppressed the potentiation by dazoxiben. The latter effect of albumin may result from its PGD isomerase activity which redirects the cyclic endoperoxide metabolism to the platelet-inhibitory PGD2. The results show that non-platelet factors such as albumin are necessary to prevent a potentiating effect of TX synthase inhibitors on platelet activation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922373     DOI: 10.1016/0006-2952(85)90488-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Thromboxane synthase inhibitors and receptor antagonists.

Authors:  J Vermylen; H Deckmyn
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

Review 2.  Current concepts for a drug-induced inhibition of formation and action of thromboxane A2.

Authors:  H Patscheke
Journal:  Blut       Date:  1990-05

3.  Effect of the PAF-receptor antagonist SM-12502 on human platelets.

Authors:  M Köller; R A Hilger; W König
Journal:  Inflammation       Date:  1996-02       Impact factor: 4.092

4.  Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.

Authors:  P Golino; M Rosolowsky; S K Yao; J McNatt; F De Clerck; L M Buja; J T Willerson
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

5.  Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.

Authors:  D J Fitzgerald; J Fragetta; G A FitzGerald
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

6.  Single dose pharmacokinetics and effects on platelet function of the thromboxane receptor blocker BM 13.177.

Authors:  C Staiger; H Patscheke; G Neugebauer; B Kaufmann; K Strein; R Endele; K Stegmeier
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.